GSK to buy US biotech firm IDRx for up to $1.15 billion

2 days ago · British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of …

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of …

reuters.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc.

2 weeks from now

2 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

gsk.com

$1.15
OFF

GSK To Buy US Cancer Biotech IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · GSK Plc agreed to buy US biotech IDRx for as much as $1.15 billion to gain new cancer medicines.. The UK drugmaker will pay $1 billion upfront for IDRx, whose lead drug for …

bloomberg.com

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion - U.S. News

2 weeks from now

2 days ago · (Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a …

usnews.com

$1.15
OFF

GSK To Buy US Cancer Biotech IDRx For Up To $1.15 Billion (1)

2 weeks from now

2 days ago · GSK Plc agreed to buy US biotech IDRx for as much as $1.15 billion to gain new cancer medicines.. The UK drugmaker will pay $1 billion upfront for IDRx, whose lead drug for …

bloomberglaw.com

$1.15
OFF

British Pharma Giant GSK To Acquire U.S. Drug Developer IDRx In …

2 weeks from now

1 day ago · British pharma giant GSK to acquire U.S. drug developer IDRx in $1.15 billion deal. BY AFP. Emma Walmsley, chief executive officer of GlaxoSmithKline (GSK). LEONARDO …

fortune.com

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · British drugmaker GSK agrees to acquire Boston-based biopharmaceutical firm IDRx for up to $1.15 billion, with an initial $1 billion payment. IDRx develops a treatment for …

indiatimes.com

$1
OFF

GSK Nears $1bn Deal For Biotech Developing Drug For Rare Tumour

2 weeks from now

Jan 8, 2025 · Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK is nearing a $1bn deal to buy a US biotech developing a treatment for rare …

ft.com

$1
OFF

GSK Nearing Deal To Acquire US Biotech IDRx For Up To $1 Billion

2 weeks from now

Jan 8, 2025 · GSK Nears Deal to Acquire US Biotech IDRx for Up to $1 Billion Jan. 08: MT GSK, Pfizer's RSV Vaccines to Warn of Neurological Disorder Risk, FDA Says Jan. 08: MT GSK …

marketscreener.com

$1
OFF

Is GSK Prepping A $1bn Takeover Bid For IDRx? | Pharmaphorum

2 weeks from now

6 days ago · GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST). …

pharmaphorum.com

$1
OFF

GSK In Talks To Buy U.S. Rare Tumor Specialist IDRx For Up To $1 ...

2 weeks from now

6 days ago · --Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 …

morningstar.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. – IDRx

2 weeks from now

2 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

idrx.com

$1
OFF

GSK Nears $1B Deal To Buy U.S. Biotech IDRx (GSK:NYSE)

2 weeks from now

Jan 8, 2025 · GSK is said to be nearing $1B deal to acquire U.S. biotech IDRx Jan. 08, 2025 10:19 AM ET GSK plc (GSK) Stock BX By: Dulan Lokuwithana , SA News Editor 2 Comments …

seekingalpha.com

$1
OFF

GSK Nears $1 Billion Deal For Biotech Company IDRx - MSN

2 weeks from now

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology portfolio.

msn.com

$1
OFF

GSK Nearing $1 Billion Deal To Acquire US Biotech IDRx, FT Reports

2 weeks from now

Jan 8, 2025 · GSK Nears Deal to Acquire US Biotech IDRx for Up to $1 Billion Jan. 08: MT GSK, Pfizer's RSV Vaccines to Warn of Neurological Disorder Risk, FDA Says Jan. 08: MT GSK …

marketscreener.com

$1
OFF

GSK Swooping To Buy US Biotech IDRx For $1bn - Report

2 weeks from now

Jan 8, 2025 · UK pharma giant GSK PLC is close to buying US biotech startup IDRx for $1 billion to boost its cancer drug business, the Financial Times has reported. ...

proactiveinvestors.co.uk

$1
OFF

GSK Swooping To Buy US Biotech IDRx For $1bn - Report

2 weeks from now

Jan 8, 2025 · UK pharma giant GSK PLC is close to buying US biotech startup IDRx for $1 billion to boost its cancer drug business, the Financial Times has reported. Backed by a raft of …

proactiveinvestors.com

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of …

marketscreener.com

$1
OFF

GSK Nears Deal To Acquire US Biotech IDRx For Up To $1 Billion

2 weeks from now

6 days ago · -- GSK is in advanced discussions to acquire closely held US biotech company IDRx for up to $1 billion, the Financial Times reported Wednesday, citing people close to the talks. …

marketscreener.com

$1
OFF

GSK Nears $1 Billion Deal For Private US Biotech IDRx, FT Reports

2 weeks from now

Jan 8, 2025 · British drugmaker GSK LSE:GSK is nearing a $1 billion deal to acquire privately-held biotech IDRx that is developing a treatment for rare type of tumor, the Financial Times …

tradingview.com

$1.15
OFF

GSK To Buy US-based IDRx For Up To $1.15 Billion To Boost ...

2 weeks from now

2 days ago · GSK Nears Deal to Acquire US Biotech IDRx for Up to $1 Billion Jan. 08: MT GSK, Pfizer's RSV Vaccines to Warn of Neurological Disorder Risk, FDA Says Jan. 08: MT GSK …

marketscreener.com

FAQs about GSK to buy US biotech firm IDRx for up to $1.15 billion Coupon?

Does GSK buy idrx?

British drugmaker GSK agrees to acquire Boston-based biopharmaceutical firm IDRx for up to $1.15 billion, with an initial $1 billion payment. IDRx develops a treatment for gastrointestinal stromal tumours, contributing to GSK's expanding portfolio in gastrointestinal cancers amid its vaccine business challenges. ...

Could GSK & idrx opt out of a biotech deal?

As discussions continue, the people added that GSK (NYSE: GSK) and IDRx could opt out of the deal, or the company will attract a new buyer. A clinical-stage biotech founded in 2022, IDRx has private equity firm Blackstone (BX) and venture capital firms Andreessen Horowitz and RA Capital among its notable investors. ...

Who owns idrx biotech?

A clinical-stage biotech founded in 2022, IDRx has private equity firm Blackstone (BX) and venture capital firms Andreessen Horowitz and RA Capital among its notable investors. Its initial product candidate, IDRX-42, targets gastrointestinal stromal tumor (GIST), a GIT cancer that affects an estimated 4,000–6,000 Americans every year. ...

Who is buying idrx?

The UK group is in advanced talks to buy privately owned biotech IDRx, which has venture capital firms Andreessen Horowitz and RA Capital as well as private equity giant Blackstone among its backers, according to people close to the discussions. ...

Will idrx go public?

IDRx had also been working on plans to go public. GSK declined to comment. IDRx did not immediately respond to request for comment. IDRx is conducting early-stage trials of its targeted therapy for patients with a type of cancer called gastrointestinal stromal tumour, or Gist, which affects between 4,000 and 6,000 people each year in the US. ...

Will GSK sell blenrep again?

GSK is seeking permission to start selling Blenrep again and forecast peak annual sales potential of more than £3 billion ($3.7 billion). Most Read from Bloomberg Can American Drivers Learn to Love Roundabouts? ...